Biotech / Medical | Provectus Pharmaceuticals Inc.


Previous 10 | Next 10 
To: TheMaster who wrote (11187)4/25/2012 11:05:02 AM
From: NTTG2 Recommendations   of 11978
 
NO, that is where I am meeting you for lunch....I was afraid this would be confusing for you.

Share Recommend | Keep | Reply | Mark as Last Read

From: okiboji4/25/2012 1:31:27 PM
   of 11978
 
bought this stock recently. what do you think the stock goes to after a derm deal? how about an onc deal? both?

Share Recommend | Keep | Reply | Mark as Last Read

To: NTTG who wrote (11186)4/25/2012 1:49:16 PM
From: PCskibum1 Recommendation   of 11978
 
I'm just why you want this company to fail so badly?

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (2)

To: PCskibum who wrote (11190)4/25/2012 2:47:06 PM
From: Mammon1 Recommendation   of 11978
 
I'm no expert on the FDA and its proceedings, but a quick google search came up with this document about Incyte's dealings with the FDA and how many iterations they went through before reaching a trial design consensus for an SPA with the FDA. The articles notes "Levy estimated the company spent about five months and went through three iterations before reaching consensus with the FDA on the SPA." And this was after a much longer period of time back and forth on the trial design.

Let me say this again, in case anyone started drinking early today. The word ITERATIONS is mentioned in the context of interfacing with the FDA regarding an acceptable trial protocol.

docs.google.com 

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: LT2011 who wrote (11183)4/25/2012 2:52:27 PM
From: Mammon2 Recommendations   of 11978
 
ah, lt2011 talking back and forth with nttg. amusing.

Share Recommend | Keep | Reply | Mark as Last Read

To: Mammon who wrote (11191)4/25/2012 3:18:07 PM
From: NTTG2 Recommendations   of 11978
 
No surprise that the FDA was willing to 'iterate' with INCYTE, presentation and published track record made them worthy partner for developing a SPA....maybe find an example closer to the PVCT model.

incyte.com 
incyte.com 

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (2)

To: NTTG who wrote (11193)4/25/2012 3:37:13 PM
From: TheMaster1 Recommendation   of 11978
 
Work in Healthcare? More like a career politician or lawyer who got caught with his hand in the cookie jar!

Share Recommend | Keep | Reply | Mark as Last Read

To: NTTG who wrote (11193)4/25/2012 3:55:32 PM
From: Mammon2 Recommendations   of 11978
 
you're just being obfuscatory now. first, it's "no iterations" then when called on the absolute wrongness of your position, it's followed by "oh, well, they'll iterate with them." Pick a choice and stick with it. You remind me of a bad trial lawyer trying to make a defense stick, any defense.

Oh, and why don't you and lt2011 talk a little more. You seem to always have fun together, you two.

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (2)

To: Mammon who wrote (11195)4/25/2012 4:09:02 PM
From: TheMaster1 Recommendation   of 11978
 
Did You read my post? He always does the exact same thing hes like an Ink Blot. Once cornered and u step on him he splashes somewhere else?

Share Recommend | Keep | Reply | Mark as Last Read

To: Mammon who wrote (11195)4/25/2012 5:21:07 PM
From: NTTG2 Recommendations   of 11978
 
Not really. The decision at 45 days is all or none. The company either gets approval based on the submission or they don't. During the review the FDA typically does not ask for supplemental information, and I have never heard of a reviewer calling the company for 'clarification' on a point. They review the application as written.

For applications that do not get approved notification may include insight on the deficiencies that need to be addressed in the revised application (generally when the company is close, I suspect per the example you cited) or they simply notify the company that the proposed study does not meet the standard (as I suspect will happen).

Either way, a new submission is the next step, and in some cases the company has to loop back to gain additional insight on where the problems were, a time consuming process for sure.

All the while the clock is ticking, and if you assume there are potential partners in the wings, they are watching.

Any luck finding an FDA approved drug that has not published this clinical trial data?

Share Recommend | Keep | Reply | Mark as Last Read
Previous 10 | Next 10 

Copyright © 1995-2013 Knight Sac Media. All rights reserved.